Mitochondrial Epilepsy (MIT-E) | Primary Research (KOL’s Insight) | Market Intelligence | Epidemiology & Market Forecast-2030
$6,500.00 – $19,500.00
The Mitochondrial epilepsy (MIT-E) therapeutic market is expected to increase at a significant rate during the figure time frame, 2021 to 2030. In 2021, the market is developing at a consistent rate and the market is relied upon to ascend over the projected horizon with the rise in adoption strategies by key market players. The therapy market is expected to experience high growth throughout our study period, increasing from 2017 to 2030.
Description
Mitochondrial epilepsy is due to mitochondrial dysfunction in patients with mitochondrial diseases (MD) and it is the common manifestation in MD patients. Most epilepsies caused by a mitochondrial disorder begin in childhood and usually in the first 2 years of life. However, seizures can begin within days of birth, or into adolescence or, rarely, into adult life.
Mitochondrial diseases are a heterogeneous group of diseases resulting from energy deficiency and reduced production of adenosine triphosphate (ATP) due to reduced oxidative phosphorylation. Epilepsy is one of the most common manifestations of diseases resulting from mitochondrial dysfunction, especially in children. However, the onset of seizures in MD patients can occur at any age. In some mitochondrial diseases, seizures are part of a syndrome, for example, in Alpers-Huttenlocher syndrome (AHS) and other phenotypes associated with a pathogenic variant in the POLG gene, pyruvate dehydrogenase complex (PDHc) deficiency, myoclonic red fiber epilepsy (MERRF), MELAS, or the syndrome by Leigh.
Mitochondrial Epilepsy – Prevalence (Epidemiology)
Prevalent cases of mitochondrial epilepsy (MIT-E) in the G7 countries are expected to increase to 82,656 cases in 2030 with a CAGR of 0.5% for the study period (2017-2030). The United States was estimated to have the highest prevalence of mitochondrial epilepsy (MIT-E) cases in 2017, among G7 countries.




Mitochondrial Epilepsy – Current Market Size & Forecast Trends
Usually, AEDs are effective in controlling seizures in nearly 70% of patients. But there is almost 30% of the population who usually do not respond to anything. This is a refractory group and falls into an unmet need. Mortality rates are highest in intensive care units, where patients often face multiple symptoms along with epilepsy and often experience coma or brain injury due to epilepsy. Emerging therapies should broaden the current disease landscape.



Report Highlights
- Mitochondrial Disorders Epilepsy -Current Market Trends
- Mitochondrial Disorders Epilepsy -Current & Forecasted Cases across the G7 Countries
- Mitochondrial Disorders Epilepsy -Market Opportunities and Sales Potential for Agents
- Mitochondrial Disorders Epilepsy -Patient-based Market Forecast to 2030
- Mitochondrial Disorders Epilepsy -Untapped Business Opportunities
- Mitochondrial Disorders Epilepsy -Product Positioning Vis-a-vis Competitors’ Products
- Mitochondrial Disorders Epilepsy -KOLs Insight
Additional information
Price | 2-3 User License, Enterprise License, Single User License, Site User License |
---|
Table of Contents
- Executive Summary
- Key Findings
- Mitochondrial Epilepsy (MIT-E) Disease Background
- Mitochondrial Epilepsy (MIT-E) Definition
- Symptoms & Causes
- Pathophysiology
- Genetic Basis of Mitochondrial Epilepsy
- Frequent Mitochondrial Diseases with Epilepsy
- Diagnosis & Diagnostic Recommendations
- Epidemiology and Patient Populations
- Key Findings
- Methods and data Sources
- Country Specific Diagnosed Prevalent Populations (US, Germany, France, Italy, Spain, UK, and Japan)
- Country Specific Mitochondrial Epilepsy Cases by Mitochondrial Disorders
- Country Specific Treated and Refractory Cases of Mitochondrial Epilepsy (MIT-E)
- Key Sources for Mitochondrial Epilepsy (MIT-E) Epidemiology and Model Parameters
- United States
- United States Prevalent Populations of Mitochondrial Epilepsy (MIT-E)
- United States Clinical Symptoms Associated Cases of Mitochondrial Epilepsy (MIT-E)
- United States Treated and Refractory Cases of Mitochondrial Epilepsy (MIT-E)
- Germany
- Germany Prevalent Populations of Mitochondrial Epilepsy (MIT-E)
- Germany Clinical Symptoms Associated Cases of Mitochondrial Epilepsy (MIT-E)
- Germany Treated and Refractory Cases of Mitochondrial Epilepsy (MIT-E)
- France
- France Prevalent Populations of Mitochondrial Epilepsy (MIT-E)
- France Clinical Symptoms Associated Cases of Mitochondrial Epilepsy (MIT-E)
- France Treated and Refractory Cases of Mitochondrial Epilepsy (MIT-E)
- Italy
- Italy Prevalent Populations of Mitochondrial Epilepsy (MIT-E)
- Italy Clinical Symptoms Associated Cases of Mitochondrial Epilepsy (MIT-E)
- Italy Treated and Refractory Cases of Mitochondrial Epilepsy (MIT-E)
- United States
-
-
- Spain
- Spain Prevalent Populations of Mitochondrial Epilepsy (MIT-E)
- Spain Clinical Symptoms Associated Cases of Mitochondrial Epilepsy (MIT-E)
- Spain Treated and Refractory Cases of Mitochondrial Epilepsy (MIT-E)
- United Kingdom
- United Kingdom Prevalent Populations of Mitochondrial Epilepsy (MIT-E)
- United Kingdom Clinical Symptoms Associated Cases of Mitochondrial Epilepsy (MIT-E)
- United Kingdom Treated and Refractory Cases of Mitochondrial Epilepsy (MIT-E)
- Japan
- Japan Prevalent Populations of Mitochondrial Epilepsy (MIT-E)
- Japan Clinical Symptoms Associated Cases of Mitochondrial Epilepsy (MIT-E)
- Japan Treated and Refractory Cases of Mitochondrial Epilepsy (MIT-E)
- Spain
-
- Current Therapies and Medical Practice
- Treatments & Medical Practices
- Pharmacological Approach
- Non-Pharmacological Approach
- Unmet Needs & Mitochoindrial Associations
- Emerging Therapies
- Pipeline Overview
- Therapeutic Developments Pipeline for Mitochondrial Epilepsy (MIT-E)
- Product Analysis
- Vatiquinone (PTC Therapeutics)
- Product Profile
- Clinical Development
- Sales & Market Opportunity by 2030
- Triheptanoin (Ultragenyx Pharmaceutical Inc)
- Product Profile
- Clinical Development
- Sales & Market Opportunity by 2030
- ABI-009 (Abraxis Bioscience/Aadi Bioscience)
- Product Profile
- Clinical Development
- Sales & Market Opportunity by 2030
- Sonlicromanol (Khondrion)
- Product Profile
- Clinical Development
- Sales & Market Opportunity by 2030
- Vatiquinone (PTC Therapeutics)
- Product Analysis
-
-
-
- CY-6463 (Cyclerion Therapeutics)
- Product Profile
- Clinical Development
- KL1333 (Abliva (NeuroVive Pharmaceutical))
- Product Profile
- Clinical Development
- CY-6463 (Cyclerion Therapeutics)
-
-
- Mitochondrial Epilepsy (MIT-E)- Pricing & Reimbursement
- Future Treatment Paradigm
- Mitochondrial Epilepsy (MIT-E) Competitor Landscape and Approvals Anticipated
- Future Treatment Algorithms and Competitor Positioning
- Key Data Summary for Emerging Treatment
- Annual Cost of Current & Emerging Therapies
- Market Outlook
- Key Findings
- Country Specific Market Forecast to 2030
- Sales of Drugs to Treat Mitochondrial Epilepsy (MIT-E) in the Major Pharmaceutical Markets, 2017-2030
- Patient Share of Mitochondrial Epilepsy (MIT-E) Therapies and by Drug
- Market Forecast by Country
- United States
- United States Market for Mitochondrial Epilepsy (MIT-E) 2020-2030 (USD Million)
- United States Market for Mitochondrial Epilepsy (MIT-E) by Therapies 2020-2030 (USD Million)
- Germany
- Germany Market for Mitochondrial Epilepsy (MIT-E) 2020-2030 (USD Million)
- Germany Market for Mitochondrial Epilepsy (MIT-E) by Therapies 2020-2030 (USD Million)
- France
- France Market for Mitochondrial Epilepsy (MIT-E) 2020-2030 (USD Million)
- France Market for Mitochondrial Epilepsy (MIT-E) by Therapies 2020-2030 (USD Million)
- Italy
- Italy Market for Mitochondrial Epilepsy (MIT-E) 2020-2030 (USD Million)
- Italy Market for Mitochondrial Epilepsy (MIT-E) by Therapies 2020-2030 (USD Million)
- Spain
- Spain Market for Mitochondrial Epilepsy (MIT-E) 2020-2030 (USD Million)
- Spain Market for Mitochondrial Epilepsy (MIT-E) by Therapies 2020-2030 (USD Million)
- United Kingdom
- United Kingdom Market for Mitochondrial Epilepsy (MIT-E) 2020-2030 (USD Million)
- United Kingdom Market for Mitochondrial Epilepsy (MIT-E) by Therapies 2020-2030 (USD Million)
- Japan
- Japan Market for Mitochondrial Epilepsy (MIT-E) 2020-2030 (USD Million)
- Japan Market for Mitochondrial Epilepsy (MIT-E) by Therapies 2020-2030 (USD Million)
- United States
- Market Drivers and Constraints
- What Factors Are Driving the Market for Mitochondrial Epilepsy (MIT-E)?
- What Factors Are Constraining the Market for Mitochondrial Epilepsy (MIT-E)?
You may also like…
-
Progressive Supranuclear Palsy (PSP) | Primary Research (KOL’s Insight) | Market Intelligence | Epidemiology & Market Forecast-2030
$6,500.00 – $19,500.00Progressive supranuclear palsy (PSP) treatment landscape reflects a huge unmet need, as it is quite dry and limited to symptomatic and supportive care, with no disease-modifying therapies. Emerging therapies like RT-001 (Retrotope), Fasudil (Woolsey), Ezeprogind (AlzProtect), Emeramide (EmeraMed) and Droxidopa (H. Lundbeck) has the potential to overcome the challenges associated with the current therapeutic options in future. Sales of these emerging therapies to treat Progressive Supranuclear Palsy (PSP) in the countries under study (United States, France, Germany, Italy, Spain, United Kingdom, and Japan) will experience high growth over the 2020-2030 study period, adding an estimated value to a total $1.3 billion market by 2030.
-
Corticobasal Syndrome (CBS) | Primary Research (KOL’s Insight) | Market Intelligence | Epidemiology & Market Forecast-2030
$6,500.00 – $19,500.00Corticobasal syndrome (CBS) is characterized by lowest clinical diagnostic accuracy, with the highest clinical presentation found in corticobasal degeneration (CBD). Current Corticobasal syndrome (CBS) treatment is limited to levodopa, commonly prescribed medication for the treatment of Parkinson’s disease. Thus, there is a huge unmet need for a medical treatment to improve the quality of life. Emerging therapies like Rho-kinase inhibitor- Fasudil (Woolsey Pharmaceuticals) have the potential to overcome the treatment barrier. Corticobasal syndrome market size will reflect high growth from 2025-2030 due to launch of Fausdil (Woolsey) in the market from 2025 year.